Market Access & Reimbursement

Securing early access and reimbursement for your products

Veristat Market Access team members provide strategic advice on national early access programs, write HTA/reimbursement dossiers for submission to national HTA bodies and prepare documentation for liaison with private healthcare insurance.

Furthermore, our team supports clients with joint EMA/HTA scientific advice meetings to optimize development plans for successful regulatory and reimbursement approvals.

It's never to early to start.   Let's Talk. 

Reimbursement Solutions Across the Clinical Development and Commercialization Lifecycle

Market Access Roadmap

  • - P&R Strategy
  • - Routes to Market Access
  • - Early Access Reimbursement
  • - Value-based contract solution
drug and biologic market access roadmap

Health Technology Assessment (HTA)

  • - Dossier strategy
  • - Value dossier
  • - National HTA dossiers
  • - Price review
health technology assessment for market access and reimbursement

Pricing

  • - Competitor Analysis
  • - Pricing Analyses & Strategy
  • - Negotiation
  • - Price Optimization tactics
people_working_handsoverpapers

Payor Authority Management

  • - Payor and HCP Research
  • - Objection Handling
  • - Advisory Boards
  • - KOL liaison
people_working_image11


Ready to develop your reimbursement strategy?

LET'S TALK

Learn More with These Resources

Blog

Veristat Global Policy Insights Q2
DOWNLOAD

Blog

Monthly FDA Guidance and Regulatory News Review - June 2024
DOWNLOAD

Blog

FSP/Resourcing: Meeting the Moment with Expert Resources
DOWNLOAD